Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) insider Suma Krishnan sold 200 shares of the firm's stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $150.14, for a total value of $30,028.00. Following the sale, the insider owned 1,463,511 shares in the company, valued at $219,731,541.54. This trade represents a 0.01% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Suma Krishnan also recently made the following trade(s):
- On Thursday, July 10th, Suma Krishnan sold 6,927 shares of Krystal Biotech stock. The stock was sold at an average price of $150.27, for a total value of $1,040,920.29.
- On Thursday, July 10th, Suma Krishnan sold 6,800 shares of Krystal Biotech stock. The stock was sold at an average price of $150.28, for a total value of $1,021,904.00.
Krystal Biotech Trading Down 1.0%
Shares of KRYS traded down $1.57 during midday trading on Friday, reaching $148.17. 267,497 shares of the company were exchanged, compared to its average volume of 287,362. The stock has a 50-day moving average price of $135.82 and a 200-day moving average price of $156.26. The company has a market cap of $4.28 billion, a price-to-earnings ratio of 35.62 and a beta of 0.67. Krystal Biotech, Inc. has a 1-year low of $122.80 and a 1-year high of $219.34.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing analysts' consensus estimates of $1.38 by ($0.18). The company had revenue of $88.18 million for the quarter, compared to analyst estimates of $98.66 million. Krystal Biotech had a return on equity of 14.64% and a net margin of 37.17%. Equities research analysts anticipate that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Financiere des Professionnels Fonds d investissement inc. acquired a new position in shares of Krystal Biotech during the second quarter worth about $162,000. Parallel Advisors LLC increased its position in shares of Krystal Biotech by 7.6% during the second quarter. Parallel Advisors LLC now owns 1,863 shares of the company's stock worth $256,000 after acquiring an additional 132 shares during the last quarter. Strs Ohio purchased a new stake in shares of Krystal Biotech during the first quarter worth about $1,244,000. Intech Investment Management LLC increased its position in shares of Krystal Biotech by 11.4% during the first quarter. Intech Investment Management LLC now owns 12,078 shares of the company's stock worth $2,178,000 after acquiring an additional 1,239 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Krystal Biotech by 173.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company's stock worth $103,764,000 after acquiring an additional 365,304 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company's stock.
Wall Street Analyst Weigh In
A number of brokerages recently weighed in on KRYS. Chardan Capital reiterated a "buy" rating and issued a $219.00 target price on shares of Krystal Biotech in a report on Wednesday, May 7th. Citigroup reiterated a "neutral" rating and issued a $176.00 target price (up previously from $155.00) on shares of Krystal Biotech in a report on Wednesday. Guggenheim reduced their target price on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Finally, HC Wainwright reiterated a "buy" rating and issued a $240.00 target price on shares of Krystal Biotech in a report on Tuesday, June 24th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Krystal Biotech currently has an average rating of "Buy" and an average target price of $213.75.
Get Our Latest Research Report on KRYS
Krystal Biotech Company Profile
(
Get Free Report)
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Further Reading
Before you consider Krystal Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.
While Krystal Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
